THRB and thyroid gland follicular carcinoma: Indeed, exogenous expression of THRB in human follicular thyroid cancer (FTC) cells (FTC-133 and FTC-236) reduced cell proliferation and impaired cell migration through inhibition of the PI3K-AKT-mTOR pathway.